MRK's lead BACE inhibitor - MK-8931 I thought they will do a smaller phase II for safety and biomarkers data only. So according to today's PRinitially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.How long will this phase II be? and why treat "mild-to-moderate" when we know chances are moderate is too late?